medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-3-18-23medsovet-54Research ArticleСАХАРНЫЙ ДИАБЕТDIABETES MELLITUSМесто инсулинотерапии в современных подходах к лечению сахарного диабета 2-го типаPlace of insulin therapy in current approaches to the treatment of type 2 diabetesГуроваО. Ю.GurovaO. Y.noemail@neicon.ruФадеевВ. В.FadeevV. V.noemail@neicon.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияFirst Moscow State Medical University named after I.M. SechenovRussian Federation201630122016031823Copyright © Гурова О.Ю., Фадеев В.В., 20162016Гурова О.Ю., Фадеев В.В.Gurova O.Y., Fadeev V.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/54

Сахарный диабет 2-го типа (СД2) является фактором высокого риска в отношении развития макро-сосудистых осложнений. Ряд проведенных крупномасштабных исследований продемонстрировал основополагающую роль раннего интенсивного гликемического контроля в предотвращении указанных осложнений. Агрессивная тактика достижения нормогликемии у пациентов с СД 2-го типа с уже имеющимися макрососудистыми осложнениями способна приводить к увеличению частоты сердечно-сосудистых исходов, что имеет четкую взаимосвязь с гипогликемическими состояниями. Инсулинотерапия (ИТ) по-прежнему относится к самым эффективным фармакологическим методам лечения диабета при правильном и своевременном назначении. Появление длительно действующих аналогов инсулина не только позволило снизить частоту гипогликемий как одного из клинически наиболее важных нежелательных явлений ИТ, но и обозначило определенные перспективы в отношении профилактики развития сахарного диабета 2-го типа у лиц с предиабетом.

Type 2 diabetes mellitus (T2DM) is a high risk factor for the development of macrovascular complications. Several large studies have demonstrated the fundamental role of early extensive blood glucose control in the prevention of these complications. An aggressive approach in achieving normoglycemia in patients with T2DM and existing macrovascular complications could lead to an increase in cardiovascular outcomes, which has a clear association with hypoglycemic conditions. Insulin therapy (IT) remains one of the most effective pharmacological treatments for diabetes provided adequate and timely prescription. The advent of long-acting insulin analogues helped not only to reduce the incidence of hypoglycemia as one of the most clinically relevant adverse events of IT, but also marked certain prospects in the prevention of type 2 diabetes in people with prediabetes.

сахарный диабетинсулинаналоги инсулинасердечно-сосудистые рискигларгинdiabetes mellitusinsulininsulin analoguescardiovascular risksglargineReferencesSowers JR. Diabetes meLLitus and cardiovascular disease in women. Arch intern Med, 1998, 158: 617-621.Sowers JR. Diabetes meLLitus and cardiovascular disease in women. Arch intern Med, 1998, 158: 617-621.The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of Long-term complications in insuLin-dependent diabetes meLLitus. N. Engl. J. Med., 1993, 329: 977-86.The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of Long-term complications in insuLin-dependent diabetes meLLitus. N. Engl. J. Med., 1993, 329: 977-86.The DCCT/EDIC Study Research Group. Long-Term Effect of Diabetes and Its Treatment on Cognitive Function. N Engl J Med. May 2007; 356; 18; 1842-1852.The DCCT/EDIC Study Research Group. Long-Term Effect of Diabetes and Its Treatment on Cognitive Function. N Engl J Med. May 2007; 356; 18; 1842-1852.United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive bLoodgLucose contro! with suLphonyLureas or insuLin compared with conventionaL treatment and risk of compLications in patients with Type 2 diabetes (UKPDS 33). Lancet, 1998, 352: 837-853.United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive bLoodgLucose contro! with suLphonyLureas or insuLin compared with conventionaL treatment and risk of compLications in patients with Type 2 diabetes (UKPDS 33). Lancet, 1998, 352: 837-853.Nathan DM, CLeary PA, BackLund JY et aL. Intensive diabetes treatment and cardiovascuLar disease in patients with type 1 diabetes. N. Engl. J. Med., 2005, 353: 2643-2653.Nathan DM, CLeary PA, BackLund JY et aL. Intensive diabetes treatment and cardiovascuLar disease in patients with type 1 diabetes. N. Engl. J. Med., 2005, 353: 2643-2653.Stratton IM, AdLer AI, NeiL AW et aL. Association of gLycaemia with macrovas cuLar and micro-vascuLar compLications of type 2 diabetes (UKPDS 35): prospective observationaL study. BMJ, 2000, 321: 405-412.Stratton IM, AdLer AI, NeiL AW et aL. Association of gLycaemia with macrovas cuLar and micro-vascuLar compLications of type 2 diabetes (UKPDS 35): prospective observationaL study. BMJ, 2000, 321: 405-412.Action to ControL CardiovascuLar Risk in Diabetes Study Group, Gerstein HC, MiLLer ME, Byington RP, et aL. Effects of intensive gLucose Lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358: 2545-2559.Action to ControL CardiovascuLar Risk in Diabetes Study Group, Gerstein HC, MiLLer ME, Byington RP, et aL. Effects of intensive gLucose Lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358: 2545-2559.ADVANCE CoLLaborative Group, PateL A, MacMahon S, ChaLmers J et aL.: Intensive bLood gLucose controL and vascuLar outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 358: 2560-2572.ADVANCE CoLLaborative Group, PateL A, MacMahon S, ChaLmers J et aL.: Intensive bLood gLucose controL and vascuLar outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 358: 2560-2572.SkyLer S, BergenstaL R, Bonow R et aL. Intensive GLycemic ControL and the Prevention of CardiovascuLar Events: ImpLications of the ACCORD, ADVANCE, and VA Diabetes TriaLs. Diabetes Care, 2009, 32(1): 187-192.SkyLer S, BergenstaL R, Bonow R et aL. Intensive GLycemic ControL and the Prevention of CardiovascuLar Events: ImpLications of the ACCORD, ADVANCE, and VA Diabetes TriaLs. Diabetes Care, 2009, 32(1): 187-192.HoLman RR, PauL SK, BetheL MA et aL. 10-year foLLow-up of intensive gLucose controL in type 2 diabetes. N. Engl J. Med., 2008, 359: 1577-1589.HoLman RR, PauL SK, BetheL MA et aL. 10-year foLLow-up of intensive gLucose controL in type 2 diabetes. N. Engl J. Med., 2008, 359: 1577-1589.Дедов И.И., Шестакова М.В., Александров А.А. и др. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» (7-й выпуск). Под ред. И.И. Дедова, М.В. Шестаковой (7-й выпуск). Cахарный диабет. 2015.Дедов И.И., Шестакова М.В., Александров А.А. и др. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» (7-й выпуск). Под ред. И.И. Дедова, М.В. Шестаковой (7-й выпуск). Cахарный диабет. 2015.StumvoLL M, GoLdstein B, Van Haeften B, Pathohenesis of type 2 diabetes. Endocr.res, 2007, 32(1-2): 19-37.StumvoLL M, GoLdstein B, Van Haeften B, Pathohenesis of type 2 diabetes. Endocr.res, 2007, 32(1-2): 19-37.Kostev K, MergenthaLer U. Time to insuLin initiation, gLucose controL and occurrence of diabetes reLated compLications in France, Germany and UK from 2005 to 2010. Diabetologia, 2011, 54, 1(SuppL. 1): S159.Kostev K, MergenthaLer U. Time to insuLin initiation, gLucose controL and occurrence of diabetes reLated compLications in France, Germany and UK from 2005 to 2010. Diabetologia, 2011, 54, 1(SuppL. 1): S159.CaLvert MJ et aL. Br J Gen Pract., 2007, 57(539): 455-460.CaLvert MJ et aL. Br J Gen Pract., 2007, 57(539): 455-460.Ray KK, Seshasai SR, Wijesuriya S et aL. Effect of intensive controL of gLucose on cardiovascuLar outcomes and death in patients with diabetes meLLitus: a meta-anaLysis of randomised controLLed triaLs. Lancet, 2009, 373, 9677: 1765-1772.Ray KK, Seshasai SR, Wijesuriya S et aL. Effect of intensive controL of gLucose on cardiovascuLar outcomes and death in patients with diabetes meLLitus: a meta-anaLysis of randomised controLLed triaLs. Lancet, 2009, 373, 9677: 1765-1772.Lepore M, PampaneLLi S, FaneLLi C et aL. Pharmacokinetics and pharmacodynamics of subcutaneous injection of Long-acting human insuLin anaLog gLargine, NPH insuLin and uLtra-Lente human insuLin and continuous infusion of insuLin Lispro. Diabetes, 2000, 49: 2142-48.Lepore M, PampaneLLi S, FaneLLi C et aL. Pharmacokinetics and pharmacodynamics of subcutaneous injection of Long-acting human insuLin anaLog gLargine, NPH insuLin and uLtra-Lente human insuLin and continuous infusion of insuLin Lispro. Diabetes, 2000, 49: 2142-48.Heinemann L, Linkeschova R, Rave K, Hompesch B, SedLak M, Heise T. Time-action profiLe of the Long-acting insuLinanaLog insuLin gLargine (HOE901) in comparison with thoseof NPH insuLin and pLacebo. Diabetes Care, 2000, 23(5): 644-9.Heinemann L, Linkeschova R, Rave K, Hompesch B, SedLak M, Heise T. Time-action profiLe of the Long-acting insuLinanaLog insuLin gLargine (HOE901) in comparison with thoseof NPH insuLin and pLacebo. Diabetes Care, 2000, 23(5): 644-9.Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, WiLson CA. LesshypogLycemia with insuL-ingLarginein intensive insuLin therapy for type 1 diabetes. U.S. Study Group of InsuLin GLargine in Type 1 Diabetes. Diabetes Care, 2000, 23(5): 639-43.Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, WiLson CA. LesshypogLycemia with insuL-ingLarginein intensive insuLin therapy for type 1 diabetes. U.S. Study Group of InsuLin GLargine in Type 1 Diabetes. Diabetes Care, 2000, 23(5): 639-43.Monami M, Marchionni N, Mannucci E. Long-acting insuLin anaLogues vs. NPH human insuLin in type 1 diabetes. Ameta- anaLysis. Diab Obes Metab., 2009, 11: 372-8.Monami M, Marchionni N, Mannucci E. Long-acting insuLin anaLogues vs. NPH human insuLin in type 1 diabetes. Ameta- anaLysis. Diab Obes Metab., 2009, 11: 372-8.Wang L, Wei W, Miao R, et aL. ReaL-worLd outcomes ofUS empLoyees with type 2 diabetes meLLitus treated withinsuLin gLargine or neutraL protamine Hagedorn insuLin: a comparative retrospective database study. BMJ Open, 2013, 3: e002348.Wang L, Wei W, Miao R, et aL. ReaL-worLd outcomes ofUS empLoyees with type 2 diabetes meLLitus treated withinsuLin gLargine or neutraL protamine Hagedorn insuLin: a comparative retrospective database study. BMJ Open, 2013, 3: e002348.Origin TriaL Investigators. RationaLe, design, and baseLine characteristics for a Large internationaL triaL of cardiovascuLar disease prevention in peopLe with dysgLycemia: the ORIGIN TriaL (Outcome Reduction with an InitiaL GLargine Intervention). Am. Heart J., 2008, 155, 1: 26-32, 32.e1-6.Origin TriaL Investigators. RationaLe, design, and baseLine characteristics for a Large internationaL triaL of cardiovascuLar disease prevention in peopLe with dysgLycemia: the ORIGIN TriaL (Outcome Reduction with an InitiaL GLargine Intervention). Am. Heart J., 2008, 155, 1: 26-32, 32.e1-6.ORIGIN TriaL Investigators. CardiovascuLar and Other Outcomes Postinterventio With InsuLin GLargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2015 Dec 17.ORIGIN TriaL Investigators. CardiovascuLar and Other Outcomes Postinterventio With InsuLin GLargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2015 Dec 17.ORIGIN TriaL Investigators. BasaL insuLin and cardiovascuLar and other outcomes in dysgLy-cemia. N. Engl. J. Med., 2012, 367, 4: 319-328.ORIGIN TriaL Investigators. BasaL insuLin and cardiovascuLar and other outcomes in dysgLy-cemia. N. Engl. J. Med., 2012, 367, 4: 319-328.BLin P, LassaLLe R, Dureau-Pournin C, Ambrosino B,Bernard MA, AboueLfath A, et aL. InsuLin gLargine and risk of cancer: a cohort study in the French NationaL HeaLth care Insurance Database. Diabetologia, 2012, 55(3): 644-53.doi:10.1007/BLin P, LassaLLe R, Dureau-Pournin C, Ambrosino B,Bernard MA, AboueLfath A, et aL. InsuLin gLargine and risk of cancer: a cohort study in the French NationaL HeaLth care Insurance Database. Diabetologia, 2012, 55(3): 644-53.doi:10.1007/Owens DR. GLargine and cancer: can we now suggest cLosure? Diabetes Care, 2012, 35(12): 2426-8. doi:10.2337/dc12-1968.Owens DR. GLargine and cancer: can we now suggest cLosure? Diabetes Care, 2012, 35(12): 2426-8. doi:10.2337/dc12-1968.Dedov I.I., Shestakova M.V., Aleksandrov A.A. et al. Clinical guidelines: Algorithms of specialized medical care to patients with diabetes (vol. 7). Edited by I.I. Dedov, M.V. Shestakova (Vol. 7). Sakharniy Diabet. 2015Dedov I.I., Shestakova M.V., Aleksandrov A.A. et al. Clinical guidelines: Algorithms of specialized medical care to patients with diabetes (vol. 7). Edited by I.I. Dedov, M.V. Shestakova (Vol. 7). Sakharniy Diabet. 2015

The authors declare that there are no conflicts of interest present.